cyrilzakka/clinical-trials huggingface dataset:
Multitarget Stool FIT-DNA Study for Colorectal Cancer Early Screening in China

The primary objective is to determine the diagnostic sensitivity and specificity of the newly developed multitarget FIT-DNA Colorectal Cancer (CRC) screening test (ColoClear) for detecting advanced neoplasia (including colorectal cancer and advanced adenomas) in high risk patients, using colonoscopy as the reference method. The secondary objective is to compare the screening performance of the multitarget FIT-DNA test with commercially available FIT (Fecal Immunochemical Test) assay in detecting advanced neoplasia.

The study will be carried out in 8 tier-3A hospitals throughout China. Patients who are at high risk of developing colorectal cancer and willing to conduct colonoscopy examination will be asked to collect stool sample prior to bowl preparation for multitarget FIT-DNA test and commercially available FIT assay. Colonoscopy and histopathologic examination are used as reference.

Eligibility Criteria:
Inclusion Criteria:

* Willing to provide written consent
* Able to provide stool sample

For high risk CRC screening group:

* Scheduled for colonoscopy voluntarily or by physician prescription
* CRC high risk profile as defined below:
* History of FIT positivity
* Family history of CRC
* Any of two of the following clinical symptoms: chronic constipation/diarrhea, stool with mucous, chronic appendicitis, chronic bilary track diseases, mental stress

For CRC group:

* Confirmed CRC patients
* No prior treatment with chemotherapy, radiotherapy, and prior to any surgical procedures

Exclusion Criteria:

* Unwilling to provide stool samples
* FAP (familial adenomatous polyposis), Crohn's disease, ulcerative colitis
* Prior history of colonoscopy within the past 5 years and removal of lesions
* History of CRC
* other conditions deemed not suited for the study by investigators
Effectiveness of Conservative Interventions in the Treatment of Trigger Finger

There is no study in the literature comparing the effectiveness of ESWT and splint therapy, which are the most commonly used approaches in the treatment of Trigger Finger (TF). The aim in this study is to investigate the effectiveness of ESWT and splint therapy used in the treatment of TF.

Volunteer patients who were clinically diagnosed with trigger finger by consulting a doctor at Etlik City Hospital, Hand Surgery Clinic will be included in the randomized controlled prospective study. Patients will be randomly divided into three groups using the 'Random Sequence Generator tab' on Random.org, a randomization website, and different treatment programs will be applied. ESWT application to a group; splint treatment with ESWT to the second group; The third group will receive only splint treatment. ESWT application will be performed on A1 puley at 15 Hz, 1000 shock wave impuls and 2.0 bar level, for a total of 5 sessions, one week apart. In addition to ESWT with the same parameters, a trigger finger splint that immobilizes the MCP joint will be recommended to the ESWT and splint treatment group. The patient will be asked to use this splint throughout the day for 8 weeks. The Splint Group will be offered the same trigger finger splint and will be asked to use it throughout the day for 8 weeks. Evaluation and measurements will be repeated for all three groups before treatment, immediately after treatment (8th week) and 4 weeks after the end of treatment (12th week). The number of individuals to participate in the study was calculated as 54 in total, with 18 people in each group (ESWT Group, ESWT+ Splint Group and Splint Group), according to the power and sample size analysis based on 80% power and 5% Type 1 error rate. Power analysis was performed based on pain intensity as the clinical endpoint.

Eligibility Criteria:
Inclusion Criteria:

* Volunteering
* Being between the ages of 18-65
* Being diagnosed with stage 1 or stage 2 (according to the Froimson classification) trigger finger
* Having the language and cognitive skills to answer the questionnaires used in the evaluation

Exclusion Criteria:

* Being pregnant
* Having an inflammatory disorder
* Having had surgery on the hand/wrist
* Having a neurological disease
* NSAIDs, painkillers, etc. being on medication
* De Quervain's tenosynovitis, carpal tunnel syndrome
Antimicrobial Prophylaxis in Thyroid and Parathyroid Surgery

The effectiveness of antimicrobial prophylaxis (AMP) for prevention of surgical site infection (SSI) following thyroid and parathyroid surgery remains uncertain. Present prospective randomized control study (Ito-RCT1) assessed the effectiveness of AMP in clean neck surgery associated with thyroid and parathyroid disease.

Between November 2010 and April 2012, 2164 consecutive patients who agreed to attend the randomized control study were enrolled. All the participants received surgery for thyroid and parathyroid disease at Ito Hospital and randomized in three groups; Group A (n=541): operation with AMP (PIPC, piperacillin sodium), Group B (n=541): operation with AMP (CEZ, cefazolin sodium), and Group C (n=1082): operation without AMP.

Exclusion criteria

* Patients who did not agree to attend the randomized control study.
* Patients who received the operation including mediastinum with sternotomy.
* Patients who received the operation including additional resection of trachea, esophagus and larynx.
* Patients who received the re-operation for post-operative bleedings.
* Patients who had known allergy to cephem or penicillin.

Eligibility Criteria:
Inclusion Criteria:

* Between November 2010 and April 2012, 2164 consecutive patients who agreed to attend the randomized control study were enrolled. All the participants received surgery for thyroid and parathyroid disease at Ito Hospital.

Exclusion Criteria:

* Patients who did not agree to attend the randomized control study.
* Patients who received the operation including mediastinum with sternotomy.
* Patients who received the operation including additional resection of trachea, esophagus and larynx.
* Patients who received the re-operation for post-operative bleedings.
* Patients who had known allergy to cephem or penicillin.
Clinical Characterization of Very and Extremely Preterm Infants Who Received Excess Erythrocyte Transfusions With Respect to HAS 2014 Recommendations

Prematurity affects around 60,000 births a year in France. Extremely premature babies are particularly fragile and require multiple erythrocyte transfusions to maintain an effective hemoglobin level for metabolism and continued somatic and neurological development. Many known risk factors, such as multiple blood sampling for biological diagnosis, lead to a more rapid fall in hemoglobin concentration, reducing the amount of oxygen delivered in the tissues. In addition, red blood cell regeneration is very low in premature infants, while the half-life of red blood cells is shorter than in older children and adults. The result is severe anemia. Its main treatment is erythrocyte transfusion. It is associated with biological benefits, but has digestive, ophthalmological, pulmonary, metabolic and neurological side effects. To ensure a good benefit/risk ratio, a commission of the HAS issued recommendations in 2014 for erythrocyte transfusion in premature infants \< 32 weeks of amenorrhea in France. Yet many transfusions continue to be performed outside the HAS 2014 criteria. A retrospective monocentric study was carried out in order to understand this situation. Data from premature infants \< 31 weeks of amenorrhea (wks) born between July 2022 and July 2024 were collected via computerized hospitalization records (DxCare, Diane and Demserv software). Their transfusion status during the first twenty-eight days of life was analyzed. The HAS decision algorithm was used to identify excess transfusions and develop a patient classification.


Eligibility Criteria:
Inclusion Criteria:

* age : ≤ 28 days of life
* Premature newborn with term of birth \< 31 weeks hospitalized in intensive care or neonatology intensive care at CHU Amiens-Picardie (CHU-AP) between July 2022 and July 2024, whether born at CHU-AP maternity unit or transferred secondarily

Exclusion Criteria:

* Newborn with term of birth ≥ 31 weeks and \> 28 days of life
Cognitive Behavioral Therapy for Depression: Helping Clients Learn New Skills

The purpose of this study is to compare two psychological treatments for major depressive disorder (MDD): cognitive-behavioral therapy (CBT) and CBT-Skill Enhanced (CBT-SE). CBT is well-studied, research-supported treatment for depression. CBT-SE is a variant of CBT that places greater focus on helping clients to developing the skills of CBT.

The study will enroll 150 participants with MDD. Participants will be randomized to CBT or CBT-SE, with 75 participants being assigned to each condition. For both conditions, treatment will be provided over 12 weeks, with a 6 month follow-up period.

Potential participants are asked to complete an initial screening and an intake evaluation to determine eligibility. After entering the study, participants are asked to complete evaluations at 4 weeks and at 12 weeks. They are also asked to respond to self-report instruments before and after each session. Following the 12 week treatment, participants are asked to complete monthly follow-up surveys for 6 months.

The primary objectives of this study are three-fold. The first is to compare the outcomes of the two treatments. The second is to evaluate potential mediators of any treatment differences. The third is to evaluate the process of change in these two versions of CBT.


Eligibility Criteria:
Inclusion Criteria:

1. diagnosis of major depressive disorder (MDD) according to DSM-5 criteria;
2. 18 years old or older;
3. residence in the state of Ohio;
4. access to a reliable internet connection (to participate in virtual sessions); and
5. being able and willing to give informed consent.

Exclusion Criteria:

1. current or past diagnosis of bipolar disorder or a psychotic disorder;
2. moderate or severe substance use in the past 6 months (where "moderate" is defined as 4-5 symptoms and "severe" is defined as 6 + symptoms of those listed in DSM-5 for each of the substance-related disorders);
3. current disorder other than MDD if it constitutes the predominant aspect of the clinical presentation and if it requires treatment other than that being offered;
4. currently participating in a treatment for an emotional disorder, including any individual psychotherapy or psychiatric medications used to treat a mood or anxiety disorders;
5. clear indication of secondary gain (e.g., court-ordered treatment); and
6. current suicide risk or significant intentional self-harm in the last six months sufficient to preclude treatment on an outpatient basis.
The Impact of Riboflavin on the Severity and Duration of Sports Related Concussion

The purpose of this study is to investigate the effectiveness of riboflavin to decrease the duration of time for a student-athlete to return to participation in sports after a sports related concussion.


Eligibility Criteria:
Inclusion Criteria:

* All UVa and JMU student-athletes over the age of 18 years old who are diagnosed with a sports related concussion

Exclusion Criteria:

* Less than 18 years old
* Greater than 24 hours have elapsed since the concussion occurred.
* The student-athlete has already participated in the study during which he/she took Riboflavin
* Non-sports related concussion not incurred while participating in the sport or training for the sport. As an example, a student-athlete who sustains a concussion as a result of a motor vehicle accident will be excluded from the study for that concussion
Quantitative Ablation of Pulmonary Vein Vestibule in Paroxysmal Atrial Fibrillation.

The purpose of this trial is to explore the optimal AI value for isolating the pulmonary veins and achieving left ventricular apex and mitral isthmus block. Patients with atrial fibrillation who are scheduled to undergo catheter ablation will be randomized to different groups, then every group receive circumferential pulmonary vein isolation with different AI values. The relevant indicators such as the proportion of pulmonary vein single-circle isolation, operation time, the incidence of complications, and the proportion of recurrence of atrial fibrillation and other atrial arrhythmias after 1 year were collected.

This is a prospective, single-center, randomized controlled trial. In this part,a total of 90 patients with paroxysmal atrial fibrillation who are scheduled for catheter ablation were randomly divided into 3 groups, 30 patients in each group. For the first group, the AI target value for the front wall and the top wall is 550, and the rear wall and the lower wall are 400. For the second group, the AI target values for the front wall and the top wall are 500, the rear wall and the lower wall are 350. For the third group, the AI target values for the front wall and top wall are 450, the rear wall and the lower wall are 300. The pressure value at each point is 5-15 g, and the distance between adjacent ablation points is less than 5 mm. The relevant indicators such as single-circle isolation rate of the pulmonary vein, operation time, the left atrial operation time, and the supplemental ablation site are recoded. The incidence of intraoperative and postoperative complications such as stroke, pericardial tamponade and steam pop during ablation are observed. Dynamic electrocardiography is performed during the follow-up period to evaluate the proportion of sinus rhythm within 1 year.

Eligibility Criteria:
Inclusion Criteria:

1. Male and non-pregnant female subjects, 18≤age≤80.
2. Receiving or able to tolerate anticoagulant therapy.
3. Diagnosis of atrial fibrillation using an electrocardiogram or a dynamic electrocardiogram
4. The longest duration of atrial fibrillation episode is less than 7 days
5. Patient is compliant and willing to complete clinical follow-up.

Exclusion Criteria:

1. Patients who have previously undergone catheter ablation of atrial fibrillation;
2. Left ventricular ejection fraction \<35%;
3. Pregnancy, planned pregnancy or lactating women;
4. Left atrial appendage thrombosis was detected by transesophageal ultrasound or intracardiac ultrasound;
5. Abnormal blood system or liver and kidney function;
6. Combined with severe organic heart disease (including congenital heart disease, valvular heart disease, dilated cardiomyopathy, hypertrophic cardiomyopathy, and patients with myocardial infarction or coronary artery bypass grafting);
7. Patients who are considered unsuitable for inclusion by the investigator.
Can the Use of Uricap Female Device Lead to Better Care for Women > 75+Years?

The purpose of the study is to evaluate if Uricap Female, an uridome for women, can be used instead of traditional incontinence aids to treat urinary incontinence (UI) among women 75 years and older.

The aim is to improve the care for female patients in long-term nursing homes who suffer from UI and to prevent recurrent urinary tract infections (UTIs).

The project organization consist of researchers within primary care, geriatrics and nursing sciences. The investigators will recruit study participants with UI from long-term nursing homes in Örebro County that will be randomized in an open randomised controlled trial to an intervention or a control group. The intervention will last for 3 months. The study participants will receive a structured medical assessment before and after the intervention, including assessment of the patient's cognitive functions, genital skin status, neuropsychiatric symptoms and quality of life (QoL).

The uridome is changed daily while the control group will receive usual incontinence treatment. The investigators will study the number of UTIs during the intervention period, analyze inflammatory cytokines in urine using OLINK proteomics and ELISA to study inflammation. Health economic analysis will be performed.

The investigators believe that treatment with Uricap Female will be more effective in preventing recurrent UTIs, improve genital skin status, cognitive status and neuropsychiatric symptoms and QoL for the women. This will directly lead to individualised care and less strain on primary care resources.

Eligibility Criteria:
Inclusion Criteria:

* UI that requires incontinence aids
* Suitable anatomy (outer labia cover and protect the Uricap Female cup).

Exclusion Criteria:

* active UTI
* urinary retention (cannot empty the bladder on her own)
* macroscopic hematuria
* prolapse or similar gynecological disorders
* allergy to silicone or latex (the material of Uricap Female)
* short expected survival time
Antagonist Protocol in Poor Responders

The effect of use of the growth hormone with antagonist protocol on the outcome of the IVF/ICSI cycles in poor responders.

Two groups of poor responder female patients planned to receive the antagonist IVF/ICSI protocol are randomized to whether or not to add growth hormone to their protocol.

Eligibility Criteria:
Inclusion Criteria:

* females fulfilling the criteria of the ESHRE consensus 2011:
* at least two of the following three features must be present:
* dvanced maternal age (≥40 years) or any other risk factor for POR
* previous POR (≤3 oocytes with a conventional stimulation protocol)
* an abnormal ovarian reserve test (i.e. AFC ,5-7 follicles or AMH ,0.5 -1.1 ng/ml).

Exclusion Criteria:

* women who suffer from any other cause of infertility other than poor ovarian reserve
* refusal of the patient to consent for using her data in the study.
Hidradenitis Suppurativa Mail Survey

Hidradenitis Suppurativa (HS), also known as "acne inversa," is a chronic dermatologic disease affecting apocrine gland-bearing areas and presenting with symptoms ranging from pustules and inflammatory nodules to draining sinuses, abscesses, and fistulae. The pain and odorous lesions associated with HS contribute to its heightened impact on quality of life in comparison to other diseases; it has been described as "one of the most distressing conditions observed in dermatology." Though it is clear that HS has a significant impact on quality of life, how this manifests remains poorly characterized. The aim of this study is to characterize the quality of life impact of HS and to validate a tool for patients to self-assess the severity of their condition.

Running a comprehensive study and asking patients what challenges they encounter in their daily lives can shed light on the ways in which HS causes quality of life impairment. In this study, the study team aims to identify the following: problems faced by patients with HS, the rate of depression, the rate of stigmatization, the rate of fear of being accepted in society, treatments that patients have tried (and which treatments seem to have worked best), the rate of alternative treatment use, and the correlation of these factors with the severity of disease.

Eligibility Criteria:
Inclusion Criteria:

* Patients diagnosed with Hidradenitis Suppurativa by a dermatologist at Wake Forest Baptist Medical Center's dermatology clinic.
* Patients 18 years of age or older

Exclusion Criteria:

* Patients younger than 18 years of age
* Any patient who does not have a mailing address on file
Interprofessional Group Intervention to Enhance Compassion Satisfaction and Resilience

The purpose of this study is to evaluate an educational professional development program designed to assist health care professionals in developing self-awareness and self-care choices as a means to avoid compassion fatigue and improve resilience.

Professional caregivers are at risk of compassion fatigue due to the nature of their work and repeated exposure over time to work-related stressors. Symptoms of compassion fatigue may include decreased concentration/productivity, increased sick days, and high turnover rates which directly effect patient satisfaction and safety. Lack of data that supports this use of program, though anecdotally, it has been endorsed and benefits from its use are described. Quality of patient care, workforce engagement, and financial effects from turnover of staff are viewed as negative impacts from compassion fatigue.

Our study seeks to extend the body of knowledge with regard to use of a particular resilience program that has shown some promise in a small pilot study.

Eligibility Criteria:
Inclusion Criteria:

* employment within inpatient or outpatient setting in non-profit healthcare system as a healthcare professional
* Professional direct caregivers (nurses, physicians, advanced practice providers, social workers, counselors, chaplains, respiratory therapists, pharmacists

Exclusion Criteria:

* actively participating in or plans to participate in any other formalized mindfulness-based stress reduction program during the time period of the study
Transcultural and Psychometric Validation of SUSHI and HOOS-12 Scores in Patients With Coxofemoral Pathologies

The management of coxofemoral pathologies is constantly increasing.

In addition to degenerative hip pathology, the orthopedic surgeon is now confronted with pathologies such as femoro-acetabular conflict, pathologies of the gluteus medius and pathologies of the labrum whose early management limits arthritis degeneration. These pathologies are mainly encountered in young subjects (\<60 years).

Self-questionnaires play an important role in understanding patients' point of view on the impact of their coxofemoral pathologies and also allow an assessment of their condition after treatment.

For the evaluation of coxofemoral pathologies in the young subject (\<60 years) the Super Simple Hip score (SUSHI-score) was developed and validated.

In the elderly subject with hip osteoarthritis, the HOOS score has the advantage of specifically measuring pain, symptoms, function and quality of life, but is made up of 40 items and is often considered rather heavy to submit. However, it has recently been simplified and the HOOS-12 (HOOS score with 12 items) has been developed and validated.

These two scores are useful in current clinical practice but they are only validated in English.


Eligibility Criteria:
Inclusion Criteria:

* Adult patient (age greater than or equal to 18 years old),
* Patient with coxofemoral pathology,
* Patient having been informed of the research,
* Patient agreeing to participate in the study.

Exclusion Criteria:

* Minor patient,
* Pregnant woman,
* Patient out of state to agree to participate in the study,
* Patient unable to answer a self-assessment questionnaire,
* Patient under justice, guardianship or curatorship,
* Patient who refused to participate in the study.